*Actavis launches $21 billion bond deal. *Exxon Mobil to sell $7 billion in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record, according to Thomson Reuters unit IFR.» Read More
With a big drug finishing its Phase III trial, this stock could be ready to move.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.
In the "Sunday Styles" section of "The New York Times" the paper runs a very prestigious weekly feature known as "Vows". It's a relatively long write-up of someone's wedding and accompanied by pictures from the event. Yesterday, the Times highlighted the ceremony of Andrew Solomon and John Habich (for at least a few years now, The Times has included same-sex partnerships in its "Weddings/Celebrations").
Johnson & Johnson said on Monday its board of directors approved the repurchase of up to $10 billion of its common stock.
Big contract wins and corporate dealmaking were some of the catalysts behind Monday's most actively traded stocks.
Roche has signed a deal worth up to $1 billion with Alnylam Pharmaceuticals, giving it access to the U.S. firm's skills in the new science of silencing genes to fight disease.
Warm weather and corporate announcements were some of the catalysts behind the most actively traded stocks on Friday.
Genzyme said Friday its experimental drug tolevamer, a treatment for diarrhea associated with the intestinal infection Clostridium difficile, worked no better than a standard antibiotic, sending the company's shares down more than 5 percent.
Shares in Belvedere jumped 7% Friday as the French wine and spirits group said it will sell its Pulco and Sirop Sport businesses to Orangina Group for 178 million euros ($242.9 million).
Below the fold on today's front page of the "The Washington Post" is an article headlined, "FDA Delay in Cancer Therapy is Attacked". It begins with an anecdote that I had reported a month ago during our live coverage from ASCO--that the outspoken critics of Dendreon's Provenge had hired private security to protect them during the cancer conference because they'd allegedly received threats from Provenge proponents. Most of the article covers familiar ground...
Business has continued to boom at the Chicago Board Options Exchange. The exchange said after the market closed Monday that average daily volume during the month of June was up 24% to 3.5 million contracts, compared with 2.9 million contracts during June 2006. Average daily volume jumped 20% during the second quarter.
The 4th of July arrived a day early for investors in Dendreon. The stock is up, yet again, on heavy volume this morning after I reported on a new review published in the journal of the American Association of Cancer Research about therapeutic cancer vaccines (see video below). Dendreon's Provenge is a therapeutic vaccine. That means it's given after you get the disease to try to power your own immune system to combat it. It shouldn't be confused with traditional preventive vaccines which are given to hopefully keep you from coming down with something.
Shares of band Tyco International and its spun-off units Covidien and Tyco Electronics, declined on Monday in their first official day of trading as separate entities.
Bayer CEO Werner Wenning signalled that the company is set to take a break from big acquisitions after a spate of deals that have catapulted it into leading positions in healthcare and crop science.
Rite Aid, the third-largest U.S. drugstore chain, posted a higher quarterly profit Thursday as an income tax benefit and a gain on asset sales offset acquisition costs.
The battle between two drug giants over the cervical cancer vaccine market is heating up. A study being published in the British medical journal, "The Lancet," says GlaxoSmithKline's shot called "Cervarix" may be different from Merck's Gardasil.
Shares of the wildly popular and volatile Dendreon were treading water on unremarkable, relatively low volume for most of the day today. Then, all of a sudden, around 2:30 there was a big spike in the stock and volume surged. With less than 15 minutes left until the closing bell more than 11 million shares have been traded. The daily average recently is nearly 24 million. The shares are up more than 10%. There's still a large, but smaller (month over month) short interest in the stock.
The huge auditorium at the McCormick Place Convention Center was packed to the rafters. It was standing room only in the 45-hundred seat theater, although the fire department wouldn't let people stand. The doctors, scientists, and educators at the American Diabetes Association's Annual Meeting came to see the rock stars of their world--Dr. Steven Nissen who wrote the controversial New England Journal of Medicine report questioning the safety of GlaxoSmithKline's Avandia and Dr. Phillip Home who wrote--also in NEJM--the subsequent interim analysis of a GSK-sponsored study that, so far, supports Avandia's safety.
Ventana told its shareholders Tuesday it recommends they "take no action at this time" in response to a $3 billion hostile takeover bid from Swiss drug maker Roche.
Shares of Ventana Medical Systems soared on Tuesday, on news that Roche Holding made a $3 billion tender offer for the company.